137242-41-2Relevant academic research and scientific papers
Diels-alder reactions with ethyl 1-benzofuran-3-carboxylates
Kil'Met'Ev,Shul'Ts,Shakirov,Rybalova,Tolstikov
, (2013)
Substituted salicylaldehydes reacted with ethyl diazoacetate to give ethyl 1-benzofuran-3-carboxylates containing various substituents in the aromatic ring. The Diels-Alder reaction of these compounds with Danishefsky's diene was regioselective, and it pr
COMPOUNDS AND USES THEREOF
-
, (2021/08/06)
The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
BENZENE FUSED HETEROCYCLIC COMPOUND AND USE THEREOF
-
Paragraph 0255; 0256; 0258; 0259, (2019/06/17)
The present disclosure provides a benzene fused heterocyclic compound of Formula (I): wherein (A) is a single or double bond; n is 0 or 1; X is -CH2-, O, NR1, or S; A is -C(Ra1)(Ra2)(Ra3) or -N(R
SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS
-
Paragraph 0261; 0262, (2016/09/26)
Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
Facile functionalization at the C2 position of a highly substituted benzofuran
He, Shuwen,Li, Peng,Dai, Xing,McComas, Casey C.,Du, Chunyan,Wang, Ping,Lai, Zhong,Liu, Hong,Yin, Jingjun,Bulger, Paul G.,Dang, Qun,Xiao, Dong,Zorn, Nicolas,Peng, Xuanjia,Nargund, Ravi P.,Palani, Anandan
supporting information, p. 2212 - 2216 (2014/04/17)
To expedite an SAR study of the C2 position of a highly substituted benzofuran ring system, we developed a method for the preparation of a key precursor, iodide 10. From iodide 10, a diverse set of compounds with different substituents at the C2 position were prepared efficiently.
TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C
-
Page/Page column 31, (2014/08/20)
The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. I
TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C
-
Page/Page column 31; 32, (2014/08/20)
The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C
-
Page/Page column 30, (2014/08/20)
The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C
-
Page/Page column 33, (2014/08/20)
The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C
-
Page/Page column 26; 32, (2014/08/20)
The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
